India's Biocon gains after unit gets US FDA approval for bone treatment drugs

Shares of Biocon BION.NS rise 2.2% to 362.05 rupees

Pharmaceuticals co's subsidiary Biocon Biologics gets U.S. Food and Drug Administration approval for Bosaya and Aukelso

Drugs are biosimilars of Denosumab, made by U.S. pharma firm Amgen AMGN.O

Bosaya approved for treatment of postmenopausal women with osteoporosis

Aukelso approved for prevention of skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors

U.S. FDA also granted provisional interchangeability designation for both drugs

BION down ~1% YTD